Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint inhibitors and had ICI-free intervals (WJOG9616L).
Hiroaki AkamatsuShunsuke TeraokaShinkichi TakamoriSatoru MiuraHidetoshi HayashiAkito HataYukihiro ToiYoshimasa ShiraishiNobuaki MamesayaYuki SatoNaoki FuruyaJun OyanagiYasuhiro KohToshihiro MisumiNobuyuki YamamotoKazuhiko NakagawaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Even in patients who initially responded to prior ICI and had ICI-free interval, once resistance occurred, retreatment with nivolumab had limited efficacy.
Keyphrases